“…Knockdown of the lncRNA MALAT1 affected inflammation by increasing miR-146a expression in an LPS-induced acute lung injury model (177). The recombinant Schistosoma japonicum protein P40 increased the levels of miR-146a in LX-2 cells and attenuated hepatic fibrosis LFH, ligamentum flavum hypertrophy; hUCMSC-EVs, human umbilical cord mesenchymal stromal cell-derived extracellular vesicles; HLSCs-EVs, human liver stem cell-derived extracellular vesicles; PEG-PLA, polyethylene glycol-poly(lactic acid); SCCII, severe controlled cortical impact injury; NLRP3, NACHT, LRR and PYD domains-containing protein 3; NEC, necrotizing enterocolitis; hUMSC-Exos, human umbilical cord mesenchymal stem cell-derived exosomes; IRI, ischemia/reperfusion injury; hUSC-Exo, human urine-derived stem cell-derived exosomes; IRAK1, interleukin-1 receptor-associated kinase 1; TRAF6, tumor necrosis factor receptor-associated factor 6; SMA, smooth muscle actin; Col-1, collagen I. by targeting Smad4 (178). Most drugs are designed according to miR-146a function by targeting the promoter of miR-146a, while lncRNAs act via their sponging effect.…”